Uso previo de antagonistas de la angiotensina II en pacientes hipertensos hospitalizados y mortalidad por COVID-19
DOI:
https://doi.org/10.35434/rcmhnaaa.2022.153.1335Palabras clave:
COVID-19, SARS-COV-2, Antagonistas de Receptores de Angiotensina, mortalidad, HipertensiónResumen
Introducción: Actualmente existe un gran interés en establecer la relación entre la severidad de la infección por SARSCOV-2 en pacientes hipertensos usuarios de antagonistas de la angiotensina II (ARAII). Objetivo. Estudiar la relación entre el uso previo de antagonistas de la ARA II en pacientes hipertensos y la mortalidad por COVID-19. Materiales y métodos. Se realizó un estudio observacional retrospectivo en un hospital de referencia en Lima, Perú, en pacientes hipertensos hospitalizados en marzo del 2021 por COVID-19 severo. Resultados. Ingresaron al estudio 101 pacientes, con una media de edad de 70.1 + 12.0 y sexo masculino 48%. Los usuarios de ARAII fueron 45 (45.6%) y no los tomaban 56 (54.4%). El Índice de comorbilidad de Charlson fue mayor en el grupo ARAII (3.6 + 1.56 vs 3.04 + 1.24) (p<0.05). La mortalidad total y por sexo (varones vs mujeres), entre los que usaban ARAII o no, fueron 57.8% vs 62% (p = 0.633) y 36.36% vs 63.64 % (p<0.05), respectivamente. La media de la concentración de deshidrogenasa láctica fue menor en los que tomaban ARAII comparado con los no usuarios, 394.18 + 152.3 vs 503.5 + 252.7 (p<0.05); no se observó diferencia significativa en el recuento de leucocitos, niveles séricos de Proteína C Reactiva, Ferritina, dímero D y fibrinógeno. Conclusión. Entre los pacientes hospitalizados con COVID-19 con hipertensión, el uso previo de ARAII no se asoció con riesgo de mortalidad.
Descargas
Métricas
Citas
Eckenstaler R, Sandori J, Gekle M, Benndorf RA. Angiotensin II receptor type 1 – An update on structure, expression and pathology. Biochem Pharmacol [Internet]. 2021 Oct;192:114673. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0006295221002860
Zimlichman R. Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Vasc Health Risk Manag [Internet]. 2011 Dec;749. Available from: http://www.dovepress.com/differential-clinical-profile-of-candesartan-compared-to-other-angiote-peer-reviewed-article-VHRM
Hill RD, Vaidya PN. Angiotensin II Receptor Blockers (ARB) [Internet]. StatPearls. 2022. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30725712
Sommerstein R, Kochen MM, Messerli FH, Gräni C. Coronavirus Disease 2019 (COVID‐19): Do Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? J Am Heart Assoc [Internet]. 2020 Apr 9;9(7). Available from: https://www.ahajournals.org/doi/10.1161/JAHA.120.016509
Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med [Internet]. 2020 Apr;8(4):e21. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2213260020301168
Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2. Circulation [Internet]. 2005 May 24;111(20):2605–10. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.104.510461
Oscanoa TJ, Vidal X, Carvajal A, Amado J, Romero-Ortuno R. Severity of SARS-COV-2 infection and angiotensin converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. Arter Hypertens [Internet]. 2020 Sep 29;24(3):106–14. Available from: https://journals.viamedica.pl/arterial_hypertension/article/view/70334
Wang Y, Chen B, Li Y, Zhang L, Wang Y, Yang S, et al. The use of renin–angiotensin–aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID‐19 patients: A systematic review and meta‐analysis. J Med Virol [Internet]. 2021 Mar 10;93(3):1370–7. Available from: https://onlinelibrary.wiley.com/doi/10.1002/jmv.26625
Lee HW, Yoon C-H, Jang EJ, Lee C-H. Renin-angiotensin system blocker and outcomes of COVID-19: a systematic review and meta-analysis. Thorax [Internet]. 2021 May;76(5):479–86. Available from: https://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2020-215322
Lee T, Cau A, Cheng MP, Levin A, Lee TC, Vinh DC, et al. Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors. CJC Open [Internet]. 2021 Jul;3(7):965–75. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2589790X21000718
Li K, Fang Y, Li W, Pan C, Qin P, Zhong Y, et al. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). Eur Radiol [Internet]. 2020 Aug 25;30(8):4407–16. Available from: http://link.springer.com/10.1007/s00330-020-06817-6
Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol [Internet]. 1994 Nov;47(11):1245–51. Available from: https://linkinghub.elsevier.com/retrieve/pii/0895435694901295
Pranata R, Permana H, Huang I, Lim MA, Soetedjo NNM, Supriyadi R, et al. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Diabetes Metab Syndr Clin Res Rev [Internet]. 2020 Sep;14(5):983–90. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1871402120302162
Chu C, Zeng S, Hasan AA, Hocher C, Krämer BK, Hocher B. Comparison of infection risks and clinical outcomes in patients with and without SARS‐CoV‐2 lung infection under renin–angiotensin–aldosterone system blockade: Systematic review and meta‐analysis. Br J Clin Pharmacol [Internet]. 2021 Jun 18;87(6):2475–92. Available from: https://onlinelibrary.wiley.com/doi/10.1111/bcp.14660
Patoulias D, Katsimardou A, Stavropoulos K, Imprialos K, Kalogirou M-S, Doumas M. Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities. Curr Hypertens Rep [Internet]. 2020 Nov 10;22(11):90. Available from: https://link.springer.com/10.1007/s11906-020-01101-w
Bezabih YM, Bezabih A, Alamneh E, Peterson GM, Bezabhe W. Comparison of renin–angiotensin–aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes. BMC Infect Dis [Internet]. 2021 Dec 5;21(1):527. Available from: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06088-6
Bavishi C, Whelton PK, Mancia G, Corrao G, Messerli FH. Renin–angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies. J Hypertens [Internet]. 2021 Apr;39(4):784–94. Available from: https://journals.lww.com/10.1097/HJH.0000000000002784
Graham DJ, Izurieta HS, Muthuri SG, Zhang D, Sandhu AT, Lu Y, et al. Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension. J Gen Intern Med [Internet]. 2021 Dec 1;36(12):3802–9. Available from: https://link.springer.com/10.1007/s11606-021-07155-z
Rizk JG, Wenziger C, Tran D, Hashemi L, Moradi H, Streja E, et al. Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19. Drugs [Internet]. 2022 Jan 16;82(1):43–54. Available from: https://link.springer.com/10.1007/s40265-021-01639-2
Gori M, Berzuini C, D’Elia E, Ghirardi A, Bernardinelli L, Gavazzi A, et al. Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients. J Hypertens [Internet]. 2021 Dec 9;Publish Ah. Available from: https://journals.lww.com/10.1097/HJH.0000000000003059
Ma Y, Zhang Y, Li S, Yang H, Li H, Cao Z, et al. Sex Differences in Association Between Anti-Hypertensive Medications and Risk of COVID-19 in Middle-Aged and Older Adults. Drugs Aging [Internet]. 2021 Oct 18;38(10):921–30. Available from: https://link.springer.com/10.1007/s40266-021-00886-y
Blum S, Lampart M, Zhou Q, Mueller C, Osswald S, Kuster GM, et al. Antihypertensive medication and outcome in patients with COVID-19 compared to non-COVID respiratory infections. Eur Heart J [Internet]. 2021 Oct 12;42(Supplement_1). Available from: https://academic.oup.com/eurheartj/article/doi/10.1093/eurheartj/ehab724.2395/6392920
Safizadeh F, Nguyen TNM, Brenner H, Schöttker B. Association of Renin–Angiotensin–Aldosterone System inhibition with Covid‐19 hospitalization and all‐cause mortality in the UK Biobank. Br J Clin Pharmacol [Internet]. 2021 Dec 22; Available from: https://onlinelibrary.wiley.com/doi/10.1111/bcp.15192
Kuzeytemiz M, Tenekecioglu E. Effect of renin-angiotensin system blocker on COVID-19 in young patients with hypertension. J Investig Med [Internet]. 2022 Jan 5;jim-2021-002036. Available from: https://jim.bmj.com/lookup/doi/10.1136/jim-2021-002036
Rocheleau G, Lee T, Mohammed Y, Goodlet D, Burns K, Cheng M, et al. 22: ARBS AND ACE INHIBITORS ARE ASSOCIATED WITH IMPROVED OUTCOMES IN MALES HOSPITALIZED WITH COVID-19. Crit Care Med [Internet]. 2022 Jan 16;50(1):11–11. Available from: https://journals.lww.com/10.1097/01.ccm.0000806556.31179.02
Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med [Internet]. 2020 Jun 18;382(25):2431–40. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2006923
Duarte M, Pelorosso F, Nicolosi LN, Victoria Salgado M, Vetulli H, Aquieri A, et al. Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial. EClinicalMedicine [Internet]. 2021 Jul;37:100962. Available from: https://linkinghub.elsevier.com/retrieve/pii/S258953702100242X
Chen D, Li X, Song Q, Hu C, Su F, Dai J, et al. Assessment of Hypokalemia and Clinical Characteristics in Patients With Coronavirus Disease 2019 in Wenzhou, China. JAMA Netw Open [Internet]. 2020 Jun 11;3(6):e2011122. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2767008
Zhao H, Li Y, Wang D, Yuan H. ARB might be superior to ACEI for treatment of hypertensive COVID‐19 patients. J Cell Mol Med [Internet]. 2021 Dec 11;25(23):11031–4. Available from: https://onlinelibrary.wiley.com/doi/10.1111/jcmm.17051
Nejat R, Sadr AS, Freitas B, Crabttree J, Pegan SD, Tripp RA, et al. Losartan Inhibits SARS-CoV-2 Replication in Vitro. J Pharm Pharm Sci [Internet]. 2021 Jul 27;24:390–9. Available from: https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31931
Oscanoa TJ, Amado J, Vidal X, Savarino A, Romero-Ortuno R. Metformin therapy and severity and mortality of SARS-CoV-2 infection: a meta-analysis. Clin Diabetol [Internet]. 2021 May 24; Available from: https://journals.viamedica.pl/clinical_diabetology/article/view/75056
Descargas
Publicado
Cómo citar
Número
Sección
Categorías
Licencia
Derechos de autor 2022 Teodoro J. Oscanoa, Jose Amado-Tineo , Javier Matta-Pérez, Waldo Taype-Huamaní
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
